Investigarea unor markeri virali si de gazda corelati cu lipsa de raspuns la tratamentul anti-viral în hepatita cronica cu virus C (HepGen)
|
|
- Griffin Watts
- 5 years ago
- Views:
Transcription
1 Investigarea unor markeri virali si de gazda corelati cu lipsa de raspuns la tratamentul anti-viral în hepatita cronica cu virus C (HepGen) Gabriela Oprisan INCDMI Cantacuzino si consortiul proiectului HepGen
2 INFORMATII PRIVIND PROIECTUL HepGen Proiect PCCA tip 2 nr 88/2012 (HepGen): Titlu: Investigarea unor markeri virali si de gazdã corelati cu lipsa de rãspuns la tratamentul anti-viral în hepatita cronicã cu virus C Coordonator: Gabriela Oprisan- INCDMI Cantacuzino Consortiul: 4 parteneri dintre care unul este IMM (P4 =laborator clinic de genetica): P1 SVB - Spitalul Clinic de Boli Infectioase si Tropicale Dr Victor Babes P2 ICF Institutul Clinic Fundeni P3 IVN - Institutul de Virusologie Ştefan S. Nicolau P4 - PG - Personal Genetics PERIOADA de derulare Finantare: Total de la bugetul de stat: lei Total cofinatare (P4) = lei
3 Consortiul HepGen Coordonator: Institutul National de Cercetare-Dezvoltare pentru Microbiologie si Imunologie Cantacuzino Gabriela Oprisan; Sorin Dinu; Maria Condei; Monica Straut; Codruta Usein; Mihaela Oprea; Monica Delia Teleman By iayork P1: Spitalul Clinic de Boli Infectioase si Tropicale Dr. Victor Babes: Prof. Petre Iacob Calistru; Prof. Emanoil Ceausu; Alma Kosa; Gratiela Tardei; Simin Florescu; Cristiana Oprea; Claudia Leulescu; Angelica Nour; George Gherlan; Gh. Voiculescu; Simona Cazacu P2: Institutul Clinic Fundeni Prof. Mihai Voiculescu; Elena Rusu; Monica Ecobici; Laurentiu Micu; Diana Zilisteanu; Camelia Achim; Andreea Radasan; Mirela Miu; Emilia Grigore; Georgia Micu; Laura Panaiteanu; Paula Dragoescu P3: Institutul de Virusologie Stefan S. Nicolau Prof. Simona Ruta; Camelia Sultana; Carmen Diaconu; Camelia Grancea; Aura Temereanca; Petruta Mihaila P4: SC Personal Genetics Georgeta Cardos; Bogdanka Militescu; Petruta Gurban; Antonie Edu; Gabriela Bucur; Cristina Ionescu; Pompilia Apostol; Vladimir Celmare; Sonia Spandole; Eugen Radu
4 HEPATITA C * Infectia produsa de HCV, virus ARN, de polaritatea + * Genul: Hepacivirus; Familie: Flaviviridae * Transmitere : parenterala, verticala, sexuala * Necultivabil (identificat prin clonare) * Poate produce infectii persistente * > 170 mil. de purtatori (3% din populatia globului) * Prevalenta in Romania: 4.56% * Patologie: hepatita acuta, cronica, ciroza hepatica, carcinom hepatocelular *Tratamentul clasic PEG-interferon + ribavirin -Tratamentele bazate pe antivirale = DAAs (inhibitori de proteaza virala: Telaprevir, Boceprevir) - Inhibitori de polimeraza virala (Sofobuvir) etc.
5 Premizele proiectului - Raspunsul viral sustinut (SVR) se obtine numai la 40 50% dintre pacientii naivi pentru tratamentul cu interferon, infectati cu HCV genotip 1, datorită selectării mutaţiilor de rezistenţă şi a unei sensibilităţi mai scăzute la IFN/RBV a acestui genotip - Tratamentul cu PEG-IFN si ribavirina produce efecte adverse si este costisitor - Virusul: Genotipul HCV, cinetica virala si mutatiile in capsida virala (gena core) in pozitiile 70 si 91 sunt asociate cu raspunsul la tratamentul cu PEG-IFN /Ribavirina - Gazda: polimorfismul in regiunea genei IL28B ca predictor major; polimorfismul genei HLA-B27 asociat cu eliminarea virala (clearance), concentratia serologica a proteinei IP-10 cu val. predictiva negativa etc.
6 Obiective - Proiectul îsi propune să definească factorii de predictie a răspunsului la terapia PEG-IFN/RBV prin analiza integrată a factorilor virali si de gazdă - Investigarea factorilor virali asociati cu lipsa raspunsului la tratament (genotip, variabilitate, cinetica incarcaturii virale) - Analiza unor factori de gazda (genetici, serologici) corelati cu raspunsul la tratament - Evaluarea mutatiilor de rezistenta la noile antivirale (DAAs) si a factorilor predictivi - Studii epidemiologice si corelarea factorilor virali cu factorii genetici si non-genetici umani - Transferul rezultatelor proiectului la autoritatile decidente din domeniul politicii sanitare Deliverabile: - Dezvoltarea unui algoritm bazat pe factori virali si markeri genetici si serologici umani, utilizabil in predictia raspunsului la tratamentul cu antivirale - Dezvoltare si transfer de tehnologie
7 Variabilitatea genetica a HCV Niveluri la care se manifesta variabilitatea genetica: * Sase genotipuri majore cu > 30 % divergenta * Subtipuri (>80) cu 20-25% divergenta Tulpini (variante individuale) izolate in contexte epidemiologice diferite cu 5-8% divergenta * Cvasispecii heterogenitate genetica HCV la acelasi individ infectat - < 5% diferente nucleotidice Raspunsul la terapia antivirala este mai scazut pentru pacientii infectati cu subtipurile 1a, 1b si 4a si mai important pentru cei infectati genotipurile 2 si 3
8 RASPUNSUL LA TRATAMENT GHANY ET ALHEPATOLOGY, Vol. 49, No. 4, 2009 Rapid virological response (RVR) HCV - ARN negativ dupa 4 sapt. de tratament Early virological response (EVR) reducere ARN HCV de >2 log 10 fata de momentul initial (EVR partial ) sau ARN HCV negativ dupa 12 sapt. de treatment (EVR complet) End-of-treatment response (ETR) ARN HCV negativ la sfarsitul tratamentului Sustained virological response (SVR) ARN HCV negativ la 24 sapt. dupa incheierea treatmentului predictor major al raspunsului pe termen lung Nonresponder esec terapeutic dupa 24 sapt de la incheierea trat. - virologic breakthrough (negativare si reaparitie a ARN in timpul trat.) - virologic relapse (recadere) - null response (scădere < 2 log 10 a viremiei în săpt. 12, fără negativare) partial response (scădere > 2 log 10 a viremiei în săpt. 12, fără negativare)
9 FACTORII ASOCIATI CU ESECUL LA TRATAMENTUL CU IFN/RBV Tarik Asselah et. al. 2010
10 Genomul HCV
11 Genomul HCV Core R 70 > Q sau H Core L 91 > M In poziţia 70, arginina (R) este înlocuită cu glutamină (Q) sau cu histidină (H) In poziţia 91 leucina (L) este substituită cu metionină (M) Akuta N, 2005; 2006
12 MODELUL EXPERIMENTAL (I) - Studiu prospectiv cu un lot de min. 150 de pacienti naivi, recrutati de SVB si ICF - loturi retrospective cu pacienti care au incheiat tratamentul (SVB si IVN) sau pacienti care nu au raspuns la tratament (ICF) Toti pacientii semneaza un formular de consimtamant informat - Criteriile de includere/ excludere au la baza protocoalele CNAS in vigoare - Crearea unei baze de date (anonimizata) privind caracteristici socio-demografice, biologice, epidemiologice, clinice, gestionata de SVB - Analiza statistica a datelor la IC
13 MODELUL EXPERIMENTAL (II) - Evaluarea raspunsului la tratament (Viral Load) la SVB - Evaluarea fibrozei la SVB si ICF - Analiza virala/genotipare prin PCR, qpcr si secventiere la IC - Selectarea unor probe virale de catre SVB pentru secventiere nextgen la Personal Genetics (FLX 454/Roche) - Analiza informatica si design de primeri/pcr la IC, PG si IVN pentru analiza markerilor de rezistenta virala - Evaluarea unor markeri genetici umani la PG si IVN - Analiza unor markeri serologici umani la IVN - Analiza integrată a factorilor virali si de gazdă si dezvoltarea unui algoritm de predictie (consortiul HepGen)
14 METODE - Baza de date SVB In perioada noiembrie iunie 2014 au fost recrutate160 de cazuri - pacienti cu hepatita cronica C, fara coinfectii cu HBV, HIV Media de varsta este de 49 de ani (22-68 ani), 46.9% barbati. Majoritatera pacientilor din lot provin din mediul urban (73,8%), si au pregatire scolara medie sau superioara (80%). 10 dintre pacienti (6,3%) se afla la al doilea tratament antiviral Cei mai multi pacienti au declarat unul sau mai multi factori de risc pentru contactarea infectiei virale HCV: % tratamente stomatologice % transfuzii de sange % agregare familiala - 5.6% risc profesional
15 METODE - Baza de date SVB La momentul actual, dintre cei 160 de pacienti recrutati, un numar de 60 au terminat tratamentul de 48 de saptamani Dintre pacientii chestionati pentru reactii adverse (n=84),52 (61.9%) au prezentat cel putin o reactia adversa Cele mai frecvente reactii adverse evidentiate in timpul tratamentului sunt, in ordinea aparitiei: - modificarea apetitului alimentar, cu scadere ponderala - reactii adverse hematologice (anemie, neutropenie, trombopenie) - alterarea starii generale +/ - sindrom anxios depresiv
16 METODE - Baza de date SVB Analiza raspunsului virusologic pt. pacientii SVB RVR = 12% RVR partial =19% EVR = 39.8% EVR partial= 80.8% SVR = 36.4%
17 METODE - Studiu prospectiv analiza statistica realizata pe un lot de 87 de pacienti cu hepatita cronica, infectati cu HCV genotip 1b, fara coinfectii cu HBV sau HIV, au inceput trat. cu IFN/RBV - Evaluare VL (viral load) pt. RVR (4 sapt.) si EVR (12 sapt.) comparativ cu VL la initierea tratament Analiza virus: - PCR si secventiere in gena core - PCR si secventire in gena NS3 - PCR si secventiere genom HCV prin tehnica Next-generation (FLX 454/Roche) - dezvoltarea unor sisteme Real-Time PCR de tip ARMS pentru detectia mutatiilor de rezistenta virala Core 70 si 91
18 METODE Analiza genetica umana: - polimorfism in gena IL28B (SNP rs ) - polimorfisme in gena ITPA (anemie) - genotipare HLA-B27 Analiza serologica: - nivelului plasmatic al proteinei IP10 - nivelului plasmatic al proteinei scd26 Analiza statistica a fost realizata cu programul SPSS versiunea 16.0 (dr. Monica Delia Teleman, IC)
19 REZULTATE ANALIZA VIRUS Genotiparea HCV prin secventiere in gena core N = 140 (la IC) 1a 9,8% *3% 4a-2,8% *1.5% 3a-2,8% *0.5% 1b - 84,6% *92,6% *Sultana C, Oprisan G, Szmal C, Vagu C, Temereanca A, Dinu S, Teleman MD, Ruta S. Molecular epidemiology of hepatitis C virus strains from Romania. J Gastrointestin Liver Dis Sep;20(3):261-6.
20 Amino Acid Substitutions in the Hepatitis C Virus Core Region are the Important Predictor of Hepatocarcinogenesis Norio Akuta et al. HEPATOLOGY, Vol. 46, No. 5, Mutatii in core: 70 R > Q/H si 91 L > M ca predictori pentru rezistenta la tratament (PEG-IFN + ribavirin) si carcinogeneza hepatica - Proteina core are potential oncogenic la soarecii transgenici - Importanta in clinica: la pacientii din Japonia, de genotip 1b si cu mutatii de rezistenta in core, tratati in mod repetat numai cu IFN, s-a constatat reducerea riscului de carcinogeneza hepatica si cresterea ratei de supravietuire - Carcinogeneza hepatica este influentata de interactia dinamica dintre Virus Gazda si Tratament
21 Genotiparea HCV prin secventiere in gena core Alinierea secventelor aac pt vizualizarea mutatiilor Core 70 si Core 91
22 Antiviral therapy Standard of Care Yee et al - The American Journal of GASTROENTEROLOGY Pegylated interferon alfa (PegIFN) and ribavirin (RBV) for weeks,depending on the viral genotype : the advent of direct-acting-antivirals (DAAs) - the standard of care for many patients with HCV genotype 1 infection became a combination of an oral NS3 protease inhibitor boceprevir or telaprevir along with pegylated IFN (PegIFN) and ribavirin (RBV). In Romania: PegIFN + RBV DAAs in teste clinice
23 NS3 Protease (180 aa) Nina Mani, 2012 Mutatii de rezistenta la DAAs: V36, T54, T55, R155, A156, V170 etc.
24 REZULTATE ANALIZA VIRUS PCR si secventiere in gena NS3 I132 V Aliniament al secventelor proteinei NS3 (181 aac) prin programul BioEdit Mutatia de rezistenta la telaprevir I132 V preexista la pacientii naivi pentru tramentul cu antiproteaza
25 PCR si secventiere genom HCV prin tehnica Next-generation - Metode Secvențierea de mare randament (next-generation sequencing) a genomului HCV 1b (dr. Eugen Radu si drd. Sonia Spandole, PG) 11 pacienți recrutati la SVB (4 din lot retrospectiv, cu status de raspuns cunoscut 2 responderi si 2 non-responderi) Inclusa o tulpina de referinta HCV 1b, clonata intr-un plasmid - secvență de control pt NGS (pfk-con1 obtinut prin amabilitatea prof. Ralf Bartenschlager, Univ. Heidelberg) Platforma de pirosecvențiere de mare randament Genome Sequencer 454 FLX/ Roche de la Personal Genetics Număr foarte mare de fragmente de ADN relativ scurte ( baze) - într-un singur experiment pot fi citite 0,4-30 miliarde de baze (cvasispecii si variante virale rare)
26 Yao E et al, Virol J 2:88, 2005 PCR si secventiere genom HCV prin tehnica Next-generation- Metode Reverstranscriere ARN viral cu primeri specifici Nested-PCR: 3 ampliconi de aproximativ 2500 pb ( ) (drd. Sorin Dinu, IC)
27 PCR si secventiere genom HCV prin tehnica Next-generation - Metode Fragmentarea ampliconilor prin nebulizare (shotgun) Ligarea de adaptori ce includ secvențe unice, necesare multiplexării (MID) Amplificare în emulsie si pirosecvențiere
28 PCR si secventiere genom HCV prin tehnica Next-generation - Metode PROCESAREA SI ANALIZA DATELOR Achiziția de imagine, analiza primară, identificarea bazelor individuale și a calității acestora software 454 Roche Filtrarea secvențelor, asamblarea de contigi pentru fiecare pacient Vicuna Finalizarea, adnotarea secvențelor consens V-FAT Corecția erorilor de pirosecvențiere RC454 Analiza variației intrahost V-Phaser 2 Toate programele de la The Broad Institute Viral Genomics Group
29 PCR si secventiere genom HCV prin tehnica Next-generation - Rezultate - Peste 1 milion de fragmente citite totalizand 400 Mbaze - Fragmente de aprox. 450 baze Acoperirea (redundanța) citirilor pentru cazuri și control între 1410 și 5040 x Secventa control: tulpina HCV 1b con-1, clonată în plasmidul pfk, identică cu cea publicata Acoperirea pentru HCV 1b con-1
30 PCR si secventiere genom HCV prin tehnica Next-generation - Rezultate Frecvența mutațiilor non-sinonime pentru cazurile R04 și R06 (SVR)
31 PCR si secventiere genom HCV prin tehnica Next-generation - Rezultate Frecvența mutațiilor non-sinonime pentru cazurile R14 și R16 (esec terapeutic)
32 PCR si secventiere genom HCV prin tehnica Next-generation - Rezultate Frecvența mutațiilor non-sinonime pentru cazurile SVB003 și SVB011 (SVR)
33 3 kb 60 Mb A Polymorphism on Chromosome 19 Predicts SVR IL28B SNP rs SNP rs Chromosome 19 Ge D, et al. Nature. 2009;461:
34 Importance of IL28B Polymorphisms (SNP rs ) * C/C genotype is associated with a higher SVR compared with T/C or T/T Treatment-naïve, genotype 1-infected patients with IL28B genotype CT or TT have a higher SVR when treated with DAA-PegIFN and RBV as compared with PegIFN and RBV treatment alone Ge D, et al. Nature. 2009;461:
35 Markerul genetic uman IL28B SNP rs : CC asociat cu SVR TT and CT asociate cu esecul terapeutic rs Rezultate IL28B : 17.8% genotip CC 64.4% genotip CT 17.8% genotip TT Testat prin reactia de discriminare alelica - Custom TaqMan Single Nucleotide Polymorhism Genotyping Assays (Applied Biosystem) la IVN, PG
36 Studiul markerilor genetici umani ITPA si HLA-B27 Personal Genetics Asocierea dintre prezenta unei alele HLA-B27 si clearance-ul spontan al HCV (metoda PCR + hibridizarea inversa - kit IVD GenoQuick HLA-B27, HAIN) Studiul markerilor 94C>A (rs ) și IVS A>C (rs ) din gena ITPA pentru evaluarea riscului de anemie medicamentoasa severa sub trat. cu IFN/RBV prin metoda PCR-RFLP (cu enzima de restrictie XmnI) Reducerea activitatii enzimei ITPA poate reduce severitatea anemiei in grade diferite, in functie de polimorfismele existente in gena ITPA
37 Studiul markerilor genetici umani ITPA si HLA-B27 Personal Genetics Rezultate HLA-B27 Alela HLA-B27 prezenta la 6% dintre pacienti (N= 100), frecventa similara de pina la 8%, raportata in literatura pt. populatia de origine caucaziana (Neumann-Haefelin 2007) Studiul markerilor ITPA Au fost identificate genotipuri homozigote de tip sălbatic (wt), precum și genotipuri heterozigote pentru polimorfismele testate Genotipuri homozigote mutante au fost obținute numai pentru markerul ITPA IVS A>C Datele obtinute sunt comparabile cu datele raportate în literatura (polimorfismul ITPA 94C>A (rs ): alela minora A=0,081; polimorfismul IVS A>C (rs ), alela C=0,074; SNP Database, National Center for Biotechnology) dar inca nu au putut fi corelate cu anemia indusa de IFN/RBV
38 Studiul markerilor serologici umani IP10 si scd26 Institutul de Virusologie Stefan S. Nicolau Analiza serologica: Nivelul plasmatic al IP-10 (Interferon-gamma inducible protein 10) testat cu Quantikine Human CXCL10/IP-10, R&DSystems - IP10 - chemokina cu activitate chemotactica pentru limfocite, celule NK si monocite corelata cu inflamatia hepatica Nivelul plasmatic al scd26 (Human scd26 ELISA, ALPCO) Proteina CD26 este o glicoproteina de membrana dipeptidilpeptidaza (DPPIV) care cliveaza peptide - IP-10 Forma solubila scd26 descris ca un marker serologic fiabil si ieftin in evaluarea severitatii bolii hepatice la pacientii HCV (marker de inflamatie hepatica)
39 Rezultate Studiul markerilor serologici umani IP10 si scd26 Institutul de Virusologie Stefan S. Nicolau - Concentratiile scazute baseline ale IP10 si scd26 sunt direct corelate cu valori reduse baseline ale ARN HCV si cu grad mic de fibroza hepatica (p=0.04 si p=0.05) - Valori scazute baseline ale IP10 (330.2 vs pg/ml; p= 0.05) si scd26 (786.1 vs ng/ml; p= 0.03) anticipeaza RVR si a EVR complet IP10 se coreleaza negativ cu diferenta de viremie HCV dintre T0 si T12 (p=0.0017)
40 % of Total cases ANALIZA STATISTICA A DATELOR Dr. Monica Delia Teleman (UMF, IC), HepGen REZULTATE (N = 87) Interferon and Ribavirin Treatment Outcome for HCV, at 4 and 12 weeks RVR Total EVR Total EVR Total+Partial 10 0 RVR Total EVR Total EVR Total+Partial Treatment Outcome RVR, EVR 13 (14.9%) RVR total 39 (44.8%) EVR total 69 (79.3%) EVR Total + Partial
41 ANALIZA STATISTICA A DATELOR Dr. Monica Delia Teleman (UMF, IC), HepGen REZULTATE (N = 87) HCV cases by Gender % Female Male Media de varsta de 50 de ani 57 % gen feminin, mai in varsta decat cazurile de gen masculin (p in T test pentru grupe independente = 0.004)
42 Caracteristici socio-demografice vs. gen Variable/ Gender Male (No.) Female (No.) P-value* Age (yrs.) < Occupation Yes No Education < (classes) Residence Rural Urban BMI < % varsta = sau > 40 de ani * Pearson Chi2 or Fischer s Exact Test
43 RVR/EVR vs. gen Gender RVR EVR No % OR *Pvalue No % OR *Pvalue Male Female Pacientii de gen Masculin au obtinut RVR in procent mai mare (24.3.%) comparativ cu cazurile de gen Feminin (8%) (p = 0.06) * Pearson Chi2 or Fischer s Exact Test
44 RVR total vs. caract. virus/gazda Host caracteristics (baseline) (Media aritmetica +/- sd) RVR No RVR *P- Value Age (yrs.) 39.8 (13.1) 51.9 (9.9) BMI 25.2 (3.8) 25.9 (4.3) 0.6 ALT (IU/ml) (54.0) 87.5 (53.8) 0.4 Glucose (mg/dl) 91.5 (14.5) (38.3) 0.3 scd (270.6) (246.5) IP (161.6) (288.1) HCV RNA log10 (IU/ml) 4.6 (1.3) 6.1 (0.6) < * Pearson Chi2 or Fischer s Exact Test
45 EVR total vs. caract. virus/gazda Host caracteristics (baseline) (Mean +/- sd) EVR No EVR 95%CI *P- Value Age (yrs.) 46.4 (11.9) 54.3 (8.9) 3.3, BMI 25.9 (3.6) 25.7 (4.7) -2.04, ALT (IU/ml) 92.5 (62.5) 83.5 (45.0) -33.2, Glucose (mg/dl) 92.6 (14.5) (46.8) 0.5, scd (236.3) (260.8) -10.1, IP (177.2) (320.6) 95.7,326.7 <0.001 HCV RNA log10 (IU/ml) 4.6 (1.3) 6.1 (0.6) 1.04, EVR au fost mai tineri si au prezentat valori semnificativ mai mici pentru IP10, Glicemie si ARN HCV la initierea trat. (T0)
46 IL28B Characteristics(baseline) Mean (+/- sd) Genotipurile IL28 B CC CT+TT *P-value Age (yrs.) 47.0 (12.8) 51.0 (11.2) 0.18 ALT (IU/ml) (77.6) 84.7 (43.4) 0.04 Hb (dl/mg) 14.9 (1.2) 14.1 (1.1) 0.01 IP (210.5) (279.2) 0.03 CD (191.6) (257.0) 0.06 HCV RNA Log10 (IU/ml) 5.8 (1.2) 6.0 (0.7) 0.3 Pacientii cu genotip CC versus genotipurile CT/TT - mai tineri, valori ALT si Hb (T0) mai mari - valori semnificativ mai mici pentru IP10 si CD26 * T test for Means, Independent Samples.
47 RVR, EVR vs. IL28B % of Total HCV cases RVR EVR CC CT TT Il28B genotype Pacientii cu genotip IL28 B tip CC au o sansa mai mare de a obtine RVR (p= 0.01) si/sau EVR (p<0.001), comparativ cu pacientii care prezinta celelalte genotipuri. * T test for Means, Independent Samples.
48 RVR, EVR vs. gradul de fibroza % of Total HCV cases RVR EVR 10 0 F0+F1+F2 F3+F4 Fibrosis Score Exista diferente pt. obtinerea RVR si/sau EVR, bazate pe scorurile de fibroza, dar diferentele nu sunt semnificativ statistice (RVR, p value = 0.3; EVR, p-value = 0.05)
49 RVR si EVR vs. mutatiile 70, 91 in gena virala core Mutatia core 70 prefigureaza o sansa mai mica pt. obtinerea RVR (Fisher s Exact Test: p-value 0.016) Nu sunt diferente semnificative pt. obtinerea RVR pt. pacienti cu mutatia virala core 91 (OR = 2.5, Pearson Chi2 Test: p- value = 0.1) Capacitatea de a atinge EVR nu pare a fi afectata de mutatiile core 70 sau 91
50 CONCLUZII Prin analiza univariata a lotului de pacienti HepGen caracteristicile urmatoare: - varsta, genul - polimorfismul in gena IL28B - valorile baseline: Hb (mg/dl); IP10; ARN HCV (IU/ml) mutatiile in gena virala core 70 si 91 par sa fie predictori pentru evolutia buna la 4 saptamani (RVR) sau 12 saptamani (EVR) de la debutul tratamentului cu IFN/RBV
51 COMUNICARI/ PUBLICATII
52 COMUNICARI/ PUBLICATII 9-11 octombrie 2013, la Hotelul Pullman Bucuresti, ICF a organizat Al XXIII lea Congres National de Hepatologie, Al III-lea Congres dehepatologie Romano-francez si al IV Curs Balcanic de Hepatologie Prof. Dr Mihai Voiculescu Improving patient outcome using predictors of response and management of adverse events Gabriela Oprisan Viral mutations correlated with treatment response in chronic hepatitis C
53 COMUNICARI/ PUBLICATII Poster la congresul ECCMID Barcelona, 2014
54 COMUNICARI/ PUBLICATII
Rate scazute de raspuns virusologic rapid la pacienti infectati cronic VHC naivi din punct de vedere terapeutic
Rate scazute de raspuns virusologic rapid la pacienti infectati cronic VHC naivi din punct de vedere terapeutic Camelia Sultana, Gabriela Oprisan, Gratiela Tardei, Simona Ruta si Echipa Proiectului HEPGEN
More informationUNIVERSITY OF MEDICINE AND PHARMACY OF CRAIOVA DOCTORAL SCHOOL DOCTORAL THESIS
UNIVERSITY OF MEDICINE AND PHARMACY OF CRAIOVA DOCTORAL SCHOOL DOCTORAL THESIS PHARMACOGENETICS AND THE APPLICATION OF SINGLE NUCLEOTIDE POLYMORPHISMS IN RESPONSE TO PEGYLATED INTERFERON AND RIBAVIRIN
More informationElectroencephalography (EEG) alteration in Autism Spectum Disorder (ASD)
Electroencephalography (EEG) alteration in Autism Spectum Disorder (ASD) FLORINA RAD 1, CAMELIA CIOBANU 2, GIANINA ANGHEL 3, IULIANA DOBRESCU 4 ABSTRACT There is a controversial relationship between Autism
More informationInterferon-gamma Inducible Protein 10 - biomarker for treatment outcome in chronic hepatitis C
Romanian Biotechnological Letters Vol.22, No. x, Copyright 216 University of Bucharest Printed in Romania. All rights reserved ORIGINAL PAPER Interferon-gamma Inducible Protein 1 - biomarker for treatment
More informationDetection and significance of PD-1.3 SNP (rs ) and IL28B SNP (rs ) in patients with current or past hepatitis B virus (HBV) infection
Detection and significance of PD-1.3 SNP (rs11568821) and IL28B SNP (rs12979860) in patients with current or past hepatitis B virus (HBV) infection Asterios Saitis 1, Nikolaos K. Gatselis 1, Kalliopi Azariadi
More informationASSAYS UTILZIED TO MONITOR HCV AND ITS TREATMENT
ASSAYS UTILZIED TO MONITOR HCV AND ITS TREATMENT Mitchell L Shiffman, MD Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, VA Liver Institute of Virginia Education, Research
More informationTrends in Hepatitis C Virus Infection Therapy: Protease Inhibitors a Step Forward in the Era of Direct Acting Antivirals
Trends in Hepatitis C Virus Infection Therapy: Protease Inhibitors a Step Forward in the Era of Direct Acting Antivirals CRISTINA POPESCU 1, 2, SMARANDA GLIGA 1, VICTORIA ARAMĂ 1, 2 1 Matei Bals National
More informationMETFORMIN IN PREVENTIA
METFORMIN IN PREVENTIA CRESTERII IN GREUTATE INDUSE DE TRATAMENTUL ANTIPSIHOTIC: O REVIZUIRE SISTEMATICA SI META-ANALIZA BMC Psyhiatry de Silva et al. BMC Psychiatry (2016) 16:341 DOI 10.1186/s12888-016-1049-5
More informationTreatment of chronic hepatitis C in HIV co-infected patients
Treatment of chronic hepatitis C in HIV co-infected patients Vicente Soriano Department of Infectious Diseases Hospital Carlos III, Madrid, Spain The most prevalent chronic viral infections in humans HBV
More informationVirological Tools and Monitoring in the DAA Era
Virological Tools and Monitoring in the DAA Era Prof. Jean-Michel Pawlotsky, MD, PhD National Reference Center for Viral Hepatitis B, C and delta Department of Virology & INSERM U955 Henri Mondor Hospital
More informationTratamiento de la Hepatitis C Rafael Esteban Hospital General Universitario Valle de Hebrón Barcelona
Tratamiento de la Hepatitis C Rafael Esteban Hospital General Universitario Valle de Hebrón Barcelona rrent HCV Therapy 8% % sustained response 6% 4% 2% % 54-61% 41% 34% 25% 16% 6% IFN 24w IFN 48w Peg
More informationROLE OF IL28B AND ITPA POLYMORPHISMS IN DIFFERENT GENOTYPES OF HCV
ROLE OF IL28B AND ITPA POLYMORPHISMS IN DIFFERENT GENOTYPES OF HCV (Especially HCV-6) WK Seto Clinical Assistant Professor Department of Medicine Queen Mary Hospital The University of Hong Kong HCV GENOTYPES:
More informationHepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors
Hepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors Fred Poordad, MD The Texas Liver Institute Clinical Professor of Medicine University of Texas Health Science Center
More information5/12/2016. Learning Objectives. Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients
5/12/216 Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients Alexander Monto, MD Professor of Clinical Medicine University of California San Francisco San Francisco,
More informationSex differences in HIV-1 viral load and absolute CD4 cell count in long term survivors HIV-1 infected patients from Giurgiu, Romania
Revista Română de Medicină de Laborator Vol. 21, Nr. 2/4, Iunie 2013 217 Short communication DOI: 10.2478/rrlm-2013-0010 Sex differences in HIV-1 viral load and absolute CD4 cell count in long term survivors
More informationTreatment strategies for recurrent hepatitis C after living donor liver transplantation (from Kyushu University experience)
Korean Association of HBP Surgery President: Dong Wook Choi, MD, PhD, Samsung Medical Center Session : 09:50-10:50, 2 nd /3, Apr 27, 2013 Venue: Lotte Hotel, Jeju Island, Korea Session: Prevention of original
More informationProtease inhibitor based triple therapy in treatment experienced patients
Protease inhibitor based triple therapy in treatment experienced patients Universitätsklinikum Leipzig Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber
More informationAreas of Interest. HCV Epidemiology, Natural History HCV Treatment. HBV Epidemiology and Prevention. Monoinfected Coinfected
CROI 2011 UPDATE Kenneth E. Sherman, MD, PhD Gould Professor of Medicine Director, Division of Digestive Diseases Univ. of Cincinnati College of Medicine Areas of Interest HCV Epidemiology, Natural History
More informationةي : لآا ةرقبلا ةروس
سورة البقرة: اآلية HCV RELAPSERS AND NONRESPONDERS: How to deal with them? BY Prof. Mohamed Sharaf-Eldin Prof. of Hepatology and Gastroenterology Tanta University Achieving SVR The ability to achieve a
More informationHepatitis C Update. Geri Brown, M.D. Associate Professor Department of Internal Medicine March 24, 2011
Hepatitis C Update Geri Brown, M.D. Associate Professor Department of Internal Medicine March 24, 2011 Outline n Educational Objectives Epidemiology and Natural History of Hepatitis C Current Treatment
More informationTreatment Options in HCV Relapsers and Nonresponders. Raymond T. Chung, M.D.
Session IV Treatment Options in HCV Relapsers and Nonresponders Raymond T. Chung, M.D. Director of Hepatology, Massachusetts General Hospital, Associate Professor of Medicine, Harvard Medical School, Boston,
More informationHepatitis C: Management of Treatment Naïve Patients with First Line Protease Inhibitors
Hepatitis C: Management of Treatment Naïve Patients with First Line Protease Inhibitors Eric Lawitz, MD, AGAF, CPI The Texas Liver Institute Clinical Professor of Medicine University of Texas Health Science
More informationThe effect of lamivudine- versus tenofovir-containing antiretroviral regimen on hepatitis B infection in a cohort of HIV infected long term survivors
The effect of lamivudine- versus tenofovir-containing antiretroviral regimen on hepatitis B infection in a cohort of HIV infected long term survivors Aura Temereanca 1,2, Luminita Ene 3, Adelina Rosca
More informationProiect IDEI 2008 C Baicus
Scaderea ponderala involuntara Proiect IDEI 2008 C Baicus www.baicus.ro 1. Studiu descriptiv, de evaluare a spectrului etiologic al SPI 2. Studiu diagnostic de evaluare a acuratetei TNF-alfa, IL- 1 beta,
More informationShould Elderly CHC Patients (>70 years old) be Treated?
Should Elderly CHC Patients (>70 years old) be Treated? Deepak Amarapurkar Consultant Gastroenterologist & Hepatologist Bombay Hospital & Medical Research Center, Mumbai & Jagjivanram Western Railway Hospital,
More informationGlecaprevir-Pibrentasvir in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2)
Phase 3 Treatment-Experienced in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2) in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2): Study Features MAGELLAN-1 (Part 2) Trial Design: Randomized,
More informationOptimal ltherapy in non 1 genotypes:
Optimal ltherapy in non 1 genotypes: genotype 2 and 3 patients Antonio Craxì GI & Liver Unit, Di.Bi.M.I.S. University of Palermo, Italy craxanto@unipa.it Peg IFN alpha plus ribavirin : SVR rate of >80%
More informationHow to optimize current therapy for GT1 patients Shortened therapy with IFNa-based therapy
How to optimize current therapy for GT1 patients Shortened therapy with IFNa-based therapy Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber- und Studienzentrum
More informationClinical Cases Hepatitis C Naïve Patients. Rafael Esteban Liver Unit. Hospital General Universitari Vall Hebron. Barcelona.
Clinical Cases Hepatitis C Naïve Patients Rafael Esteban Liver Unit. Hospital General Universitari Vall Hebron. Barcelona. Case study 1 27 year old woman, Diagnosed with Chronic Hepatitis C 3 years ago
More informationTreatment of Hepatitis C in HIV-Coinfected Patients. Vincent Soriano Department of Infectious Diseases Hospital Carlos III Madrid, Spain
Treatment of Hepatitis C in HIV-Coinfected Patients Vincent Soriano Department of Infectious Diseases Hospital Carlos III Madrid, Spain Estimated no. of persons infected with HIV and hepatitis viruses
More informationTransplantation. Professor Didier. Centre Hépatobiliaire, Hépatobiliaire, C.H.B.
Treatment Treatment of of Hepatitis Hepatitis C C in in Liver Liver Transplantation Transplantation Professor Professor Didier Didier Samuel Samuel Centre Centre Hépatobiliaire, Hépatobiliaire, Inserm
More informationIntroduction. The ELECTRON Trial
63rd AASLD November 9-13, 12 Boston, Massachusetts Faculty Douglas T. Dieterich, MD Professor of Medicine and Director of CME Department of Medicine Director of Outpatient Hepatology Division of Liver
More informationPredictors of Response to Hepatitis C Therapy in the DAA Era. Pablo Barreiro Servicio de Enfermedades Infecciosas Hospital Carlos III, Madrid
Predictors of Response to Hepatitis C Therapy in the DAA Era Pablo Barreiro Servicio de Enfermedades Infecciosas Hospital Carlos III, Madrid Why Predicting HCV Response? Select candidates for therapy Prioritizing
More informationEPIDEMIOLOGY, CLINICAL FEATURES AND OUTCOME OF ACUTE HEPATITIS C IN HIV-POSITIVE PATIENTS: PRESENTATION OF OUR EXPERIENCE
EPIDEMIOLOGY, CLINICAL FEATURES AND OUTCOME OF ACUTE HEPATITIS C IN HIV-POSITIVE PATIENTS: PRESENTATION OF OUR EXPERIENCE E. Angeli, A. Mainini, C. Atzori, G. Gubertini and G. Rizzardini II Dept. Infectious
More informationSimeprevir + PEG + RBV in Treatment-Naïve Genotype 1 QUEST-1 Trial
Phase 3 Treatment Naïve Simeprevir + in Treatment-Naïve Genotype 1 QUEST-1 Trial Jacobson IM, et al. Lancet. 2014;384:403-13. Simeprevir + PEG + Ribavirin for Treatment-Naïve HCV GT1 QUEST-1 Trial QUEST-1
More information2.0 Synopsis. ABT-450/r, ABT-267 M Clinical Study Report R&D/17/0539. (For National Authority Use Only)
2.0 Synopsis AbbVie Inc. Name of Study Drug: ABT-450, ritonavir, ABT-267, ribavirin, pegylated interferon Name of Active Ingredient: ABT-450, Ritonavir, ABT-267, Ribavirin, Pegylated interferon Individual
More informationDisclosures 29/09/2014. Genetic determinants of. HCV treatment outcome. IDEAL: IL28B-type is the strongest pre-treatment predictor of SVR
29/9/214 Genetic determinants of ᴧ HCV treatment outcome Disclosures Advisory board member - Gilead, Abbvie, Bristol-Myers Squibb (BMS), Janssen, Merck, and oche Speaker - Gilead, Janssen, Merck, BMS,
More informationGenetic Determinants in HCV
Genetic Determinants in HCV Lynn E. Taylor, MD Assistant Professor of Medicine Warren Alpert Medical School of Brown University The Miriam Hospital Providence, RI April 27, 2011 Disclosure My presentation
More informationHepatitis C Therapy Falk Symposium September 20, 2008
Hepatitis C Therapy Falk Symposium September 20, 2008 Ira M. Jacobson, MD Vincent Astor Professor of Clinical Medicine Chief, Division of Gastroenterology and Hepatology Medical Director, Center for the
More informationCurrent Treatments for HCV
Current Treatments for HCV Mitchell L. Shiffman, MD, FACG Advisory Committee/Board Member: Achillion, Anadys, Boehringer-Ingelheim, BMS, Conatus, Genentech, Gen-Probe, Gilead, Globeimmune, GSK, Janssen,
More informationThe role of triple therapy with protease inhibitors in hepatitis C virus genotype 1na «ve patients
The role of triple therapy with protease inhibitors in hepatitis C virus genotype 1na «ve patients David R. Nelson Clinical and Translational Science Institute, University of Florida, FL, USA Liver International
More informationTECHNICAL SUMMARY OF RESULTS
TECHNICAL SUMMARY OF RESULTS 2008-004605-34 [Debio 025-HCV-205] Sponsor: Debiopharm S.A. Name of Finished Product: Tabulated Study Report (For National Authority Use Only) Name of Active Ingredient: Debio
More informationMEDIC CENTER. Case 2
Case 2 Case history 57 year old Vietnamese man He lives in HCM city and works as a engineer The patient presented in July 2012 with fatigue Diagnosed with HCV in 2004 Negative for both HBV and HIV antibodies
More informationHEPATITIS C UPDATES. Sanaa S. Said 10 th April, 2014
HEPATITIS C UPDATES Sanaa S. Said 10 th April, 2014 CONTENTS Introduction Epidemiology Transmission and Natural history Kenyan guidelines What is new? References INTRODUCTION Hepacivirus genus, Flaviviridae
More informationPersonalizzazione della Cura in Epatologia. Epatite Cronica C: Pazienti con Genotipo 2
Monotematica AISF 213 Personalizzazione della Cura in Epatologia Pisa, 17-19 Ottobre 213 Epatite Cronica C: Pazienti con Genotipo 2 Maria Grazia Rumi U.O. Epatologia, Ospedale San Giuseppe Università degli
More informationHow do you optimize HCV Treatment for Cirrhotic Patients APASL STC Cebu
How do you optimize HCV Treatment for Cirrhotic Patients APASL STC Cebu Seng Gee Lim Chairman, APASL Liver Week 2013 Professor of Medicine Dept of Gastroenterology and Hepatology NUHS, Singapore Disclosures
More informationTreating HCV Genotype 2 & 3
Treating HCV Genotype 2 & 3 3rd Workshop on HCV Therapy Advances, Rome 14.12.2013 Christoph Sarrazin Klinikum der J. W. Goethe-Universität Frankfurt am Main, Germany HCV Genotypes 2 & 3 Laurel and Hardy
More informationRolul Hepcidinei in Anemia din bolile cronice o abordare translationala. Grigoras Adelina Grigorescu Beatrice-Adriana Hluscu Otilia
Rolul Hepcidinei in Anemia din bolile cronice o abordare translationala Grigoras Adelina Grigorescu Beatrice-Adriana Hluscu Otilia Anemia din bolile cronice definitii, cauze ACD anemia cu a doua rata de
More informationSpleen assessment by Acoustic Radiation Force Impulse Elastography (ARFI) for prediction of liver cirrhosis and portal hypertension
Original papers Medical Ultrasonography 2010, Vol. 12, no. 3, 213-217 Spleen assessment by Acoustic Radiation Force Impulse Elastography (ARFI) for prediction of liver cirrhosis and portal hypertension
More informationManagement of CHC G1 patients who are relapsers or non-responders to Peg IFN and RBV therapy: Wait or Triple Therapy?
Management of CHC G1 patients who are relapsers or non-responders to Peg IFN and RBV therapy: Wait or Triple Therapy? Prof. Teerha Piratvisuth NKC Institute of Gastroenterology and Hepatology Prince of
More information29th Viral Hepatitis Prevention Board Meeting
29th Viral Hepatitis Prevention Board Meeting Madrid, November 2006 Treatment of chronic hepatitis C José M. Sánchez-Tapias Liver Unit Hospital Clínic University of Barcelona Spain CHRONIC HEPATITIS C
More informationRELEVANCE OF TRANSIENT ELASTOGRAPHY (FIBROSCAN ) IN EVALUATION OF HEPATIC B VIRUS CHRONICALLY INFECTED PATIENTS
ORIGINAL ARTICLES RELEVANCE OF TRANSIENT ELASTOGRAPHY (FIBROSCAN ) IN EVALUATION OF HEPATIC B VIRUS CHRONICALLY INFECTED PATIENTS Diana Nicolita, Ioan Sporea, Roxana Sirli, Alexandra Deleanu, Adriana Tudora,
More informationHepatitis C Management and Treatment
Hepatitis C Management and Treatment Kaya Süer Near East University Faculty of Medicine Infectious Diseases and Clinical Microbiology 1 Discovery of Hepatitis C Key facts Hepatitis C: the virus can cause
More informationVicente Soriano Department of Infectious Diseases
Predictors of Response to Hepatitis C Therapy Vicente Soriano Department of Infectious Diseases Hospital Carlos III, Madrid, Spain Diagnosis Therapy IL28B alleles Non-invasive liver fibrosis methods Viral
More informationThe HCV pipeline: Will IFN-free treatment be possible? Heiner Wedemeyer. Hannover Medical School Germany
: Will IFN-free treatment be possible? Heiner Wedemeyer Hannover Medical School Germany Interferon-free regimens to treat hepatitis C What should be the goal of interferon-free treatment regimens: Sustained
More informationICVH 2016 Oral Presentation: 28
Ledipasvir/Sofosbuvir Is Safe and Effective for the Treatment of Patients with Genotype 1 Chronic HCV Infection in Both HCV Mono- and HIV/HCV Coinfected Patients A Luetkemeyer 1, C Cooper 2, P Kwo 3, K
More informationReduced telaprevir dosing in combination therapy for patients with chronic hepatitis C
Original Contribution Kitasato Med J 2017; 47: 1-9 Reduced telaprevir dosing in combination therapy for patients with chronic hepatitis C Wataru Ando, 1 Yumi Fukunaga, 1 Hiroaki Yokomori, 2 Takako Komiyama
More informationPHYSICAL EXERCISES FOR DIABETIC POLYNEUROPATHY
STUDIA UBB EDUCATIO ARTIS GYMN., LIX, 4, 2014, pp. 101-106 (RECOMMENDED CITATION) PHYSICAL EXERCISES FOR DIABETIC POLYNEUROPATHY DOCU AXELERAD ANY 1*, DOCU AXELERAD DANIEL 2 ABSTRACT. Introduction: Chronic
More informationNew Therapies on the Horizon in Hepatitis C Patients Paul Y. Kwo, MD
Viral Targets for HCV New Therapies on the Horizon in Hepatitis C Patients Paul Y. Kwo, MD Sites for development of inhibitors Metalloproteinase Serine protease (trans) Core E E2 NS2 NS3 NS4a/NS4b NS5a/NS5b
More informationReview Will IL28B polymorphisms remain relevant to direct-acting antiviral treatment paradigms?
Antiviral Therapy 2012; 17:1163 1170 (doi: 10.3851/IMP2427) Review Will IL28B polymorphisms remain relevant to direct-acting antiviral treatment paradigms? Golo Ahlenstiel 1, David R Booth 2, Jacob George
More informationExpress Scripts, Inc. monograph dated 5/25/2011; selected revision 6/1/2011
BENEFIT DESCRIPTION AND LIMITATIONS OF COVERAGE ITEM: PRODUCT LINES: COVERED UNDER: DESCRIPTION: CPT/HCPCS Code: Company Supplying: Setting: Coverage Criteria: Approval Period: Victrelis (boceprevir capsules)
More informationHCV Resistance Associated variants: impact on chronic hepatitis C treatment
HCV Resistance Associated variants: impact on chronic hepatitis C treatment Dr. Stéphane Chevaliez Associate Professor of Medicine at the University of Paris-Est. History of Resistance in HCV Concern Only
More informationAntiviral agents in HCV
Antiviral agents in HCV : Upcoming Therapeutic Options Su Jong Yu, M.D., Ph.D. Department of Internal Medicine, Liver Research Institute, Seoul National University College of Medicine Estimated 170 Million
More informationInfluence of Baseline HCV Genotype upon Treatment Outcome of Acute HCV Infection in HIV Co-Infected Individuals
Influence of Baseline HCV Genotype upon Treatment Outcome of Acute HCV Infection in HIV Co-Infected Individuals Christoph Boesecke, Hans-Jürgen Stellbrink, Stefan Mauss, Emma Page, Mark Nelson, Sanjay
More informationThe role of physical training in lowering the cardio-metabolic risk
The role of physical training in lowering the cardio-metabolic risk Timea Szasz 1, Eugen Bota 2, Lucian Hoble 3 Abstract The cardio-metabolic risk represents the overall risk of developing type 2 diabetes
More informationDeterminants of Response to Pegylated Interferon and Ribavirin for Acute Hepatitis C Infection in Patients with Human Immunodeficiency Virus
Determinants of Response to Pegylated Interferon and Ribavirin for Acute Hepatitis C Infection in Patients with Human Immunodeficiency Virus Leah Burke, M.D. 1, Daniel Fierer, M.D. 2, David Cassagnol,
More informationEmerging Approaches for the Treatment of Hepatitis C Virus
Emerging Approaches for the Treatment of Hepatitis C Virus Gap Analysis 1 Physicians may not be sufficiently familiar with the latest guidelines for chronic HCV treatment, including the initiation and
More informationOral combination therapy: future hepatitis C virus treatment? "Lancet Oct 30;376(9751): Oral combination therapy with a nucleoside
Author manuscript, published in "Journal of Hepatology 2011;55(4):933-5" DOI : 10.1016/j.jhep.2011.04.018 Oral combination therapy: future hepatitis C virus treatment? Commentary article on the following
More informationInterferon free therapy Are we getting there? Graham R Foster Queen Marys University of London
Interferon free therapy Are we getting there? Graham R Foster Queen Marys University of London IFN free therapy Disclosures I have received personal and institutional funding from companies that sell drug
More informationASSESSMENT PRIOR TO TREATMENT DO WE NEED IL28B TESTING?
ASSESSMENT PRIOR TO TREATMENT DO WE NEED IL28B TESTING? DO WE NEED LIVER BIOPSY? Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, VA POTENTIAL
More informationHepatitis C Emerging Treatment Paradigms
Hepatitis C Emerging Treatment Paradigms David R Nelson MD Assistant Vice President for Research Professor of Medicine Director, Clinical and Translational Science Institute University of Florida Gainesville,
More informationTimisoara Physical Education and Rehabilitation Journal
DOI: 10.2478/tperj-2013-0006 Aspects Regarding the Beneficial Effect of Reflexology in Low Back Pain Şerban GLIGOR 1, Silviu ISTRATE 2 Abstract Reflexology is based on the digital pressure on certain reflex
More informationEASL 2013 Interferon Free, All Oral Regimens for Hepatitis C. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain
EASL 2013 Interferon Free, All Oral Regimens for Hepatitis C Maria Buti Hospital Universitario Valle Hebron Barcelona Spain The first Results with Oral therapy: a Protease Inhibitor and NS5A inhibitor
More informationHepatitis C Treatment 2014
Hepatitis C Treatment 214 Brendan M. McGuire, MD UAB Liver Center Outline Epidemiology/National History Terminology for Treatment Treatment Considerations Current Treatment Options Genotype 1 (GT 1) Genotype
More informationTreatement Experienced patients without cirrhosis. Rafael Esteban Hospital Universitario Valle Hebron Barcelona
Treatement Experienced patients without cirrhosis Rafael Esteban Hospital Universitario Valle Hebron Barcelona Agenda With IFN PegIFN+ Ribavirin + Simeprevir PegIFN+ Ribavirin+ Sofosbuvir Without IFN Sofosbuvir
More informationORIGINAL ARTICLE. Abstract. Introduction
ORIGINAL ARTICLE Long-term Pegylated Interferon Monotherapy Following 72 Weeks of Pegylated Interferon and Ribavirin in Hepatitis C Virus Genotype-1-infected Slow Responders Shinya Watanabe 1, Yoshimasa
More informationSYNOPSIS Final Clinical Study Report for Study AI444031
Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Name of Active Ingredient: () Individual Study Table Referring to the Dossier (For National Authority Use Only) SYNOPSIS for Study
More informationDirect acting anti-virals: the near future
Direct acting anti-virals: the near future Heiner Wedemeyer Hannover Medical School Germany Will IFN-free treatment be possible in the near future? Interferon-free regimens to treat hepatitis C What should
More informationCASE STUDY. Adverse Events in treatment chronic hepatitis C patients with PegInterferon and Ribavirin What would your management decision be?
Adverse Events in treatment chronic hepatitis C patients with PegInterferon and Ribavirin What would your management decision be? CASE STUDY Pham Thi Thu Thuy MD, PhD Ho Chi Minh City Vietnam Serious Adverse
More informationCase #1. Case #1. Case #1: Audience vote VS. The Great Debate: When to Treat HCV in our HIV coinfected patients
Case #1 The Great Debate: When to Treat HCV in our HIV coinfected patients Medical Management of AIDS December, 2012 Moderated by George Beatty,MD 35 year old African American man, CD4 + 450, HIV RNA
More informationBOCEPREVIR (BOC): EVIDENCE FROM TRIALS
BOCEPREVIR (BOC): EVIDENCE FROM TRIALS ROME, FEBRUARY 22 nd -25 th, 212 Savino Bruno, MD Department of Internal Medicine A.O. Fatebenefratelli e Oftalmico Milan, Italy Savino Bruno, MD Director of InternalMedicine,
More informationNew developments in HCV research and their implications for front-line practice
New developments in HCV research and their implications for front-line practice Dr. Curtis Cooper Associate Professor, University of Ottawa Director, Ottawa Hospital Viral Hepatitis Program June 17, 2013
More information240 TMJ 2007, Vol. 57, No. 4. Angelica Sink. abstract ORIGINAL ARTICLES
ORIGINAL ARTICLES INSULIN RESISTANCE IN PATIENTS WITH CHRONIC HEPATITIS C Angelica Sink REZUMAT Introducere: Insulinorezisten]a (IR) este factorul major n determinarea sindromului metabolic, fiind rezultatul
More informationHEPATITIS C TREATMENT GUIDANCE
HEPATITIS C TREATMENT GUIDANCE These guidelines have been produced based on the NICE Guidance TA200 Peginterferon alfa and ribavirin for the treatment of chronic hepatitis c and the summaries of product
More informationCOMPARATIVE ASSESSMENT OF POLLUTION LEVEL IN TWO INDUSTRIAL AREAS USING BIOINDICATORS
Contribuţii Botanice, XXXIX, 2004 Grădina Botanică Alexandru Borza Cluj-Napoca Katalin BARTÓK 1, Ana-Maria RUSU 2 1 Universitatea Babeş-Bolyai, Facultatea de Biologie şi Geologie, str. Republicii, nr.
More informationNew Therapeutic Strategies: Polymerase Inhibitors
New Therapeutic Strategies: Polymerase Inhibitors 6th Paris Hepatitis Conference 14 th - 15 th January, 2013 Stefan Zeuzem Goethe University Hospital Frankfurt, Germany Direct antiviral targets C E1 E2
More informationPhase 3. Treatment Experienced. Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2. Afdhal N, et al. N Engl J Med. 2014;370:
Phase 3 Treatment Experienced Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2 Afdhal N, et al. N Engl J Med. 2014;370:1483-93. Ledipasvir-Sofosbuvir +/- Ribavirin in Treatment-Experienced HCV
More informationPEARL-I. Ombitasvir + Paritaprevir + Ritonavir +/- Ribavirin in HCV GT4. Treatment Naïve and Treatment Experienced
Phase 2b Treatment Naïve and Treatment Experienced Ombitasvir + Paritaprevir + Ritonavir +/- Ribavirin in HCV GT4 PEARL-I Hézode C, et al. Lancet. 2015 March 30. [Epub ahead of print] PEARL-I: Study Design
More informationReview Article Hepatitis C Virus: A Critical Appraisal of New Approaches to Therapy
Hepatitis Research and Treatment Volume 2012, Article ID 138302, 21 pages doi:10.1155/2012/138302 Review Article Hepatitis C Virus: A Critical Appraisal of New Approaches to Therapy David R. Nelson, 1
More informationASSESSMENT OF VACCINE EFFICACY FOR DISEASES INCLUDED IN THE NATIONAL IMMUNIZATION PROGRAM FOR PRESCHOOL CHILDREN
THE JOURNAL OF PREVENTIVE MEDICINE 22; 1 (3): 45-55 ASSESSMENT OF VACCINE EFFICACY FOR DISEASES INCLUDED IN THE NATIONAL IMMUNIZATION PROGRAM FOR PRESCHOOL CHILDREN Angela Romaniuc, Anca Nistor, Cecilia
More informationGESTATIONAL LENGTH, BIRTH WEIGHT AND LATER RISK FOR DEPRESSION
GESTATIONAL LENGTH, BIRTH WEIGHT AND LATER RISK FOR DEPRESSION Valentin Matei 1, Carmen Udrea 1 1 MD Psychiatrist, Clinical Hospital of Psychiatry Prof dr Al. Obregia, Bucharest. Contact email: vm_matei@yahoo.com.
More informationThe Effect of Antiviral Therapy on Liver Fibrosis in CHC. Jidong Jia Beijing Friendship Hospital, Capital Medical University
The Effect of Antiviral Therapy on Liver Fibrosis in CHC Jidong Jia Beijing Friendship Hospital, Capital Medical University 2016-5-29 1 Disclosure Consultation for Abbvie, BMS, Gilead, MSD, Novartis and
More information19-21 octombrie 2017 Hotel Ramada Parc/Ramada Plaza, București PACHETE DE PROMOVARE
19-21 octombrie 2017 Hotel Ramada Parc/Ramada Plaza, București PACHETE DE PROMOVARE 5 Principalele coordonate ale Congresului Național de Neuropatie Diabetică și Picior Diabetic, cu participare internațională
More informationVII CURSO AVANCES EN INFECCIÓN VIH Y HEPATITIS VIRALES
VII CURSO AVANCES EN INFECCIÓN VIH Y HEPATITIS VIRALES REGIMENES TERAPÊUTICOS DE LA HEPATITIS C, INTERFERÓN FREE A Coruña 2 Febrero 2013 Rui Sarmento e Castro Centro Hospitalar do Porto HJU ECS Universidade
More informationProgram Disclosure. Provider is approved by the California Board of Registered Nursing, Provider #13664, for 1.5 contact hours.
Program Disclosure This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint-sponsorship
More informationHow to optimize treatment for HCV Genotype 4
How to optimize treatment for HCV Genotype 4 Paris Hepatitis Conference Pr Tarik Asselah 14 janvier 2014 MD, PhD Service d Hépatologie & INSERM U773 University Paris Diderot Hôpital Beaujon, Clichy tarik.asselah@bjn.aphp.fr
More informationClinical Сase A previously relapse to PEG IFN + RBV in HCV G3a patient. Konstantin Zhdanov
Clinical Сase A previously relapse to PEG IFN + RBV in HCV G3a patient Konstantin Zhdanov Genotype 3 in Europe Canada Norway Germany Sweden Czech Republic Poland Approximately 1/3 of HCV-infected patients
More informationHow to use pegylated Interferon for Chronic Hepatitis B in 2015
How to use pegylated Interferon for Chronic Hepatitis B in 215 Teerha Piratvisuth NKC Institute of Gastroenterology and Hepatology Prince of Songkla University, Thailand ASIAN-PACIFIC CLINICAL PRACTICE
More informationGHRELIN AS MARKER OF AGE ASSOCIATED CARDIO-VASCULAR DISEASE
FARMACIA, 2014, Vol. 62, 4 721 GHRELIN AS MARKER OF AGE ASSOCIATED CARDIO-VASCULAR DISEASE CLAUDIA BĂCANU, DENISA MARGINĂ*, NICULINA MITREA, NOORA WAEL RASHEED Carol Davila University of Medicine and Pharmacy,
More informationPACHETE DE PROMOVARE
PACHETE DE PROMOVARE Principalele coordonate ale Congresului Național de Neuropatie Diabetică și Picior Diabetic, cu participare internațională Neurodiab 2016 sunt: Speakeri de renume internațional Program
More information